Vertex Pharmaceuticals Incorporated (VRTX)
| Market Cap | 115.62B |
| Revenue (ttm) | 11.72B |
| Net Income (ttm) | 3.68B |
| Shares Out | 253.72M |
| EPS (ttm) | 14.22 |
| PE Ratio | 32.04 |
| Forward PE | 22.71 |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 1,337,281 |
| Open | 454.28 |
| Previous Close | 452.04 |
| Day's Range | 449.48 - 456.46 |
| 52-Week Range | 362.50 - 519.68 |
| Beta | 0.32 |
| Analysts | Buy |
| Price Target | 494.64 (+8.54%) |
| Earnings Date | Nov 3, 2025 |
About VRTX
Vertex Pharmaceuticals Incorporated, a biotechnology company, engages in developing and commercializing therapies for treating cystic fibrosis (CF). It markets TRIKAFTA/KAFTRIO for people with CF with at least one F508del mutation for 2 years of age and older; ALYFTREK for the treatment for people with CF 6 years of age and older; SYMDEKO/SYMKEVI for treatment of patients with CF 6 years of age and older; ORKAMBI for CF patients 1 year or older; and KALYDECO for the treatment of patients with 1 month or older who have CF with ivacaftor. The com... [Read more]
Financial Performance
Financial StatementsAnalyst Summary
According to 25 analysts, the average rating for VRTX stock is "Buy." The 12-month stock price target is $494.64, which is an increase of 8.54% from the latest price.
News
2 Healthcare Stocks to Buy Ahead of the New Year
CRISPR Therapeutics could soar on the back of significant pipeline progress next year. Vertex's slow and steady approach to diversifying its lineup should eventually pay off.
3 Brilliant Growth Stocks to Buy Now and Hold for the Long Term
Apple's fiercely loyal customer base gives it a built-in market for any new devices it might launch in the future. MercadoLibre is positioned to grow rapidly in the Latin America e-commerce and fintec...
Down 10%, Should You Buy the Dip on Vertex Pharmaceuticals?
Vertex Pharmaceuticals is the worldwide leader in cystic fibrosis treatment -- and its drugs have generated blockbuster revenue. The company has expanded into other therapeutic areas in recent years a...
Vertex's gene therapy shows promise in younger children with blood disorders
Vertex Pharmaceuticals said on Saturday its gene therapy helped children aged between 5 and 11 years with sickle cell disease to be free of painful events and allowed those with another blood disorder...
Vertex Presents New Data on CASGEVY®, Including First-Ever Data in Children Ages 5-11 Years, at the American Society of Hematology Annual Meeting and Announces Plan for Global Regulatory Submissions
BOSTON--(BUSINESS WIRE)--Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced data from multiple studies demonstrating the clinical benefits of CASGEVY® (exagamglogene autotemcel) in peo...
1 Reason I'll Never Sell Vertex Pharmaceuticals Stock
Vertex Pharmaceuticals dominates the cystic fibrosis treatment market and recently has expanded into other therapeutic areas. The biotech predicts full-year 2025 revenue of as much as $12 billion.
Vertex Pharmaceuticals Incorporated (VRTX) Presents at Citi Annual Global Healthcare Conference 2025 Transcript
Vertex Pharmaceuticals Incorporated (VRTX) Presents at Citi Annual Global Healthcare Conference 2025 Transcript
2 Brilliant Growth Stocks to Buy Now and Hold for the Long Term
Alphabet's advertising, cloud, and AI businesses are booming. Vertex is branching out beyond its still-successful core business.
3 Top Stocks to Buy in December
MercadoLibre has tremendous potential in the Latin American e-commerce and fintech markets. TransMedics Group is preparing to expand into Italy and has plenty of room to grow in the U.S. as well.
Where Will Vertex Pharmaceuticals Be in 5 Years
Some things will remain the same for Vertex five years from now, including its dominance in treating cystic fibrosis (CF). However, the company will likely achieve success in several new markets beyon...
2 Healthcare Stocks For Beginner Investors With a 30-Year Time Horizon
Healthcare investments tend to be less cyclical than other stocks and help diversify your portfolio. Vertex has a profitable portfolio and promising pipeline, and its growth may be just getting starte...
2 Inflation-Proof Growth Stocks That Could Outperform the Market
Vertex Pharmaceuticals' monopoly grants it significant pricing power, making it an inflation-resistant company. Mastercard's business is well-adapted to navigate inflationary periods; it also has a te...
Vertex to Participate in the Citi's 2025 Global Healthcare Conference on December 3
BOSTON--(BUSINESS WIRE)--Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced management participation in Citi's 2025 Global Healthcare Conference. Charlie Wagner, Chief Operating and Fi...
Columbia Contrarian Core Fund Q3 2025 Performance Review
The fund underperformed its benchmark, the Russell 1000 Index, during the third quarter. Videogame producer Electronic Art's was the top contributor during the period. Elevance Health was the top unde...
3 Best Healthcare Stocks: Quant Strong Buys From Goldman's 'Alpha' List
The healthcare sector's renewed momentum offers fertile ground for investors wanting to outperform by picking the best stocks from the broader indexes. Goldman Sachs identified 29 healthcare stocks in...
1 Incredible Reason to Buy Vertex Pharmaceuticals Stock in November
Vertex's core business continues to drive strong financial results. The biotech has an exciting late-stage pipeline that could make significant progress in the next few years.
PGIM Jennison Health Sciences Fund Q3 2025 Contributors And Detractors
The S&P 1500 Health Care Index advanced 4.0% in the third quarter, underperforming the S&P 500, which gained 8.1%. Stock selection within biotechnology and health care providers & services, along with...
Alger Weatherbie Specialized Growth Fund Q3 2025 Portfolio Update
Class A shares of the Alger Weatherbie Specialized Growth Fund underperformed the Russell 2500 Growth Index during the third quarter of 2025. Semtech Corporation (SMTC), Impinj Inc. (PI), and Artivion...
Vertex Pharmaceuticals Incorporated (VRTX) Presents at UBS Global Healthcare Conference 2025 Transcript
Vertex Pharmaceuticals Incorporated ( VRTX) UBS Global Healthcare Conference 2025 November 11, 2025 10:15 AM EST Company Participants Reshma Kewalramani - CEO, President & Director Conference Call Pa...
Vertex Pharmaceuticals Incorporated (VRTX) Discusses Updated Data for Pove in IgAN and pMN and Developments in Kidney Disease Portfolio Transcript
Vertex Pharmaceuticals Incorporated ( VRTX) Discusses Updated Data for Pove in IgAN and pMN and Developments in Kidney Disease Portfolio November 8, 2025 8:00 PM EST Company Participants Susie Lisa -...
Vertex Presents Updated Phase 1/2 Data From RUBY-3 Study That Continue to Demonstrate Best-in-Class Potential for Povetacicept in Adults with IgA Nephropathy and Primary Membranous Nephropathy at American Society of Nephrology Kidney Week
BOSTON--(BUSINESS WIRE)--Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced updated data for povetacicept (pove) in IgA nephropathy (IgAN) and primary membranous nephropathy (pMN) from...
Artisan Global Opportunities Fund Q3 2025 Portfolio Update
During the quarter, we initiated new positions in Spotify, L3Harris Technologies and Insmed. We also added to 3i Group, West Pharmaceutical and Amazon during the quarter. We ended our investment campa...
Vertex Pharmaceuticals: JOURNAVX Prescription Demand And Povetacicept Developments Warrant "Strong Buy"
Vertex Pharmaceuticals (VRTX) is rated as a "Strong Buy" due to robust revenue growth and multiple expansion opportunities across its pipeline. JOURNAVX drives revenue with strong acute pain demand an...
Committee stocks on the move: Uber and Vertex Pharma
The Investment Committee discuss some of their stocks on the move today.